(Q37870209)

24 August 2017

1 reference

title

Emerging drugs to treat juvenile idiopathic arthritis (English)

1 reference

juvenile rheumatoid arthritis

24 August 2017

main subject

1 reference

1

Nicolino Ruperto

1 reference

24 August 2017

Alberto Martini

2

1 reference

24 August 2017

language of work or name

English

0 references

publication date

30 April 2011

1 reference

Expert Opinion on Emerging Drugs

24 August 2017

published in

1 reference

24 August 2017

volume

16

1 reference

24 August 2017

issue

3

1 reference

24 August 2017

page(s)

493-505

1 reference

Efficacy and safety of tocilizumab in patients with systemic-onset juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled, withdrawal phase III trial

24 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.581662

Role of interleukin-1 (IL-1) in the pathogenesis of systemic onset juvenile idiopathic arthritis and clinical response to IL-1 blockade

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.581662

A diagnostic score for molecular analysis of hereditary autoinflammatory syndromes with periodic fever in children

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.581662

Neonatal-onset multisystem inflammatory disease responsive to interleukin-1beta inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.581662

Pattern of interleukin-1beta secretion in response to lipopolysaccharide and ATP before and after interleukin-1 blockade in patients with CIAS1 mutations

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.581662

A multicentre, randomised, double-blind, placebo-controlled trial with the interleukin-1 receptor antagonist anakinra in patients with systemic-onset juvenile idiopathic arthritis (ANAJIS trial)

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.581662

Anakinra as first-line disease-modifying therapy in systemic juvenile idiopathic arthritis: report of forty-six patients from an international multicenter series

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.581662

Gene expression signatures in polyarticular juvenile idiopathic arthritis demonstrate disease heterogeneity and offer a molecular classification of disease subsets

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.581662

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.581662

Patients with juvenile psoriatic arthritis comprise two distinct populations

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.581662

Use of unlabelled and off licence drugs in children. Use of unlicensed drugs may be recommended in guidelines

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.581662

International research networks in pediatric rheumatology: the PRINTO perspective

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.581662

Is it time to move to active comparator trials in juvenile idiopathic arthritis?: a review of current study designs

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.581662

Synovial and inflammatory diseases in childhood: role of new imaging modalities in the assessment of patients with juvenile idiopathic arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.581662

Methotrexate in resistant juvenile rheumatoid arthritis. Results of the U.S.A.-U.S.S.R. double-blind, placebo-controlled trial. The Pediatric Rheumatology Collaborative Study Group and The Cooperative Children's Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.581662

Leflunomide or methotrexate for juvenile rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.581662

2011 American College of Rheumatology recommendations for the treatment of juvenile idiopathic arthritis: initiation and safety monitoring of therapeutic agents for the treatment of arthritis and systemic features

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.581662

The German etanercept registry for treatment of juvenile idiopathic arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.581662

Long-term efficacy and safety of infliximab plus methotrexate for the treatment of polyarticular-course juvenile rheumatoid arthritis: findings from an open-label treatment extension.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.581662

Adalimumab with or without methotrexate in juvenile rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.581662

Safety and efficacy of combination of etanercept and methotrexate compared to treatment with etanercept only in patients with juvenile idiopathic arthritis (JIA): preliminary data from the German JIA Registry

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.581662

Malignancies in juvenile idiopathic arthritis: a preliminary report

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.581662

Abatacept in children with juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled withdrawal trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.581662

Abatacept improves health-related quality of life, pain, sleep quality, and daily participation in subjects with juvenile idiopathic arthritis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.581662

Recent developments in anti-rheumatic drugs in pediatrics: treatment of juvenile idiopathic arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.581662

Current therapeutic approaches to autoimmune chronic uveitis in children

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.581662

Development and validation of a preliminary definition of minimal disease activity in patients with juvenile idiopathic arthritis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.581662

Accuracy of Wallace criteria for clinical remission in juvenile idiopathic arthritis: a cohort study of 761 consecutive cases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.581662

Methotrexate withdrawal at 6 vs 12 months in juvenile idiopathic arthritis in remission: a randomized clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.581662

Targeting IL-17 and Th17 cells in rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.581662

IL-17 as a future therapeutic target for rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.581662

The transient nature of the Th17 phenotype.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.581662

Th17 transcription factor RORC2 is inversely correlated with FOXP3 expression in the joints of children with juvenile idiopathic arthritis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.581662

Interleukin-17-producing T cells are enriched in the joints of children with arthritis, but have a reciprocal relationship to regulatory T cell numbers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.581662

Th17 plasticity in human autoimmune arthritis is driven by the inflammatory environment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.581662

LY2439821, a humanized anti-interleukin-17 monoclonal antibody, in the treatment of patients with rheumatoid arthritis: A phase I randomized, double-blind, placebo-controlled, proof-of-concept study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.581662

Impaired T(H)17 cell differentiation in subjects with autosomal dominant hyper-IgE syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.581662

Autoantibodies against IL-17A, IL-17F, and IL-22 in patients with chronic mucocutaneous candidiasis and autoimmune polyendocrine syndrome type I

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.581662

Mixed results with modulation of TH-17 cells in human autoimmune diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.581662

Ustekinumab, a human interleukin 12/23 monoclonal antibody, for psoriatic arthritis: randomised, double-blind, placebo-controlled, crossover trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.581662

Randomized, double-blind, placebo-controlled trial of the oral interleukin-12/23 inhibitor apilimod mesylate for treatment of active Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.581662

Targeting the B Cell in Rheumatoid Arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.581662

EULAR recommendations for vaccination in adult patients with autoimmune inflammatory rheumatic diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.581662

Immunization responses in rheumatoid arthritis patients treated with rituximab: results from a controlled clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.581662

Humoral responses after influenza vaccination are severely reduced in patients with rheumatoid arthritis treated with rituximab

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.581662

The effects of rituximab on immunocompetency in patients with autoimmune disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.581662

Treatment of childhood autoimmune haemolytic anaemia with rituximab

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.581662

Rituximab therapy for refractory systemic-onset juvenile idiopathic arthritis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.581662

Rituximab therapy produced rapid and sustained clinical improvement in a patient with systemic onset juvenile idiopathic arthritis refractory to TNF alpha antagonists

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.581662

Successful treatment of refractory adult onset Still's disease with rituximab

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.581662

Phenotypic and functional characterization of switch memory B cells from patients with oligoarticular juvenile idiopathic arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.581662

Lymphoid neogenesis in juvenile idiopathic arthritis correlates with ANA positivity and plasma cells infiltration.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.581662

Therapeutic targeting of Janus kinases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.581662

Inhibition of JAK kinases in patients with rheumatoid arthritis: scientific rationale and clinical outcomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.581662

The safety and efficacy of a JAK inhibitor in patients with active rheumatoid arthritis: Results of a double-blind, placebo-controlled phase IIa trial of three dosage levels of CP-690,550 versus placebo

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.581662

Treatment of rheumatoid arthritis with a Syk kinase inhibitor: a twelve-week, randomized, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.581662

An oral spleen tyrosine kinase (Syk) inhibitor for rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.581662

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.581662

Osteoprotegerin/RANKL system imbalance in active polyarticular-onset juvenile idiopathic arthritis: a bone damage biomarker?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.581662

Denosumab prevents metacarpal shaft cortical bone loss in patients with erosive rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.581662

Osteoclast-poor human osteopetrosis due to mutations in the gene encoding RANKL.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.581662

Assessing current outcomes of juvenile idiopathic arthritis: a cross-sectional study in a tertiary center sample

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.581662

Effects of denosumab on bone mineral density and bone turnover in patients with rheumatoid arthritis receiving concurrent glucocorticoids or bisphosphonates

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.581662

Denosumab treatment effects on structural damage, bone mineral density, and bone turnover in rheumatoid arthritis: A twelve-month, multicenter, randomized, double-blind, placebo-controlled, phase II clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.581662

A randomized, placebo-controlled trial of infliximab plus methotrexate for the treatment of polyarticular-course juvenile rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.581662

10.1517/14728214.2011.581662

21 January 2018

Identifiers

DOI

1 reference

24 August 2017

1 reference